| Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas BB Ding, JJ Yu, RYL Yu, LM Mendez, R Shaknovich, Y Zhang, G Cattoretti, ... Blood, The Journal of the American Society of Hematology 111 (3), 1515-1523, 2008 | 351 | 2008 |
| An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer M Chen, J Zhang, K Sampieri, JG Clohessy, L Mendez, ... Nature genetics 50 (2), 206-218, 2018 | 268 | 2018 |
| MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia AR Pyzer, D Stroopinsky, H Rajabi, A Washington, A Tagde, M Coll, ... Blood, The Journal of the American Society of Hematology 129 (13), 1791-1801, 2017 | 150 | 2017 |
| BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy LC Cerchietti, K Hatzi, E Caldas-Lopes, SN Yang, ME Figueroa, RD Morin, ... The Journal of clinical investigation 120 (12), 4569-4582, 2010 | 148 | 2010 |
| Germline NPM1 mutations lead to altered rRNA 2′-O-methylation and cause dyskeratosis congenita D Nachmani, AH Bothmer, S Grisendi, A Mele, D Bothmer, JD Lee, ... Nature genetics 51 (10), 1518-1529, 2019 | 93 | 2019 |
| CtBP is an essential corepressor for BCL6 autoregulation LM Mendez, JM Polo, JJ Yu, M Krupski, BB Ding, A Melnick, BH Ye Molecular and cellular biology 28 (7), 2175-2186, 2008 | 83 | 2008 |
| MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs AR Pyzer, D Stroopinsky, J Rosenblatt, E Anastasiadou, H Rajabi, ... Leukemia 31 (12), 2780-2790, 2017 | 67 | 2017 |
| Deregulated PP1α phosphatase activity towards MAPK activation is antagonized by a tumor suppressive failsafe mechanism M Chen, L Wan, J Zhang, J Zhang, L Mendez, JG Clohessy, K Berry, ... Nature communications 9 (1), 159, 2018 | 49 | 2018 |
| Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy V Mugoni, R Panella, G Cheloni, M Chen, O Pozdnyakova, D Stroopinsky, ... Cell research 29 (6), 446-459, 2019 | 40 | 2019 |
| Therapeutic potential of targeting the SUMO pathway in cancer A Kukkula, VK Ojala, LM Mendez, L Sistonen, K Elenius, M Sundvall Cancers 13 (17), 4402, 2021 | 34 | 2021 |
| A non-cell-autonomous role for Pml in the maintenance of leukemia from the niche J Guarnerio, LM Mendez, N Asada, AV Menon, J Fung, K Berry, ... Nature communications 9 (1), 66, 2018 | 31 | 2018 |
| The interplay between the genetic and immune landscapes of AML: mechanisms and implications for risk stratification and therapy LM Mendez, RR Posey, PP Pandolfi Frontiers in Oncology 9, 1162, 2019 | 29 | 2019 |
| Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial AM Brunner, TM Blonquist, DJ DeAngelo, M McMasters, G Fell, ... The Lancet Haematology 7 (2), e122-e133, 2020 | 26 | 2020 |
| Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings JS Garcia, Y Flamand, L Penter, M Keng, BK Tomlinson, LM Mendez, ... Blood 141 (15), 1884-1888, 2023 | 23 | 2023 |
| Safety and efficacy from a phase 1b/2 study of IMGN632 in combination with azacitidine and venetoclax for patients with CD123-positive acute myeloid leukemia N Daver, A Aribi, P Montesinos, GJ Roboz, ES Wang, RB Walter, ... Blood 138, 372, 2021 | 23 | 2021 |
| Broad activity for the pivekimab sunirine (PVEK, IMGN632), azacitidine, and venetoclax triplet in high-risk patients with relapsed/refractory acute myeloid leukemia (AML) N Daver, P Montesinos, A Aribi, G Marconi, JK Altman, ES Wang, ... Blood 140 (Supplement 1), 145-149, 2022 | 21 | 2022 |
| A Phase I study of asciminib (ABL001) in combination with dasatinib and prednisone for BCR-ABL1-positive ALL in adults MR Luskin, KE Stevenson, LM Mendez, ES Wang, M Wadleigh, JS Garcia, ... Blood 138, 2305, 2021 | 16 | 2021 |
| VWF maturation and release are controlled by 2 regulators of Weibel-Palade body biogenesis: exocyst and BLOC-2 AV Sharda, AM Barr, JA Harrison, AR Wilkie, C Fang, LM Mendez, ... Blood, The Journal of the American Society of Hematology 136 (24), 2824-2837, 2020 | 15 | 2020 |
| Safety and efficacy of decitabine plus ipilimumab in relapsed or refractory MDS/AML in the post-BMT or transplant naïve settings JS Garcia, Y Flamand, BK Tomlinson, M Keng, LM Mendez, S Khaled, ... Blood 136, 15-17, 2020 | 15 | 2020 |
| Circulating Protein Disulfide Isomerase Is Associated with Increased Risk of Thrombosis in JAK2-Mutated Myeloproliferative Neoplasms AV Sharda, T Bogue, A Barr, LM Mendez, R Flaumenhaft, JI Zwicker Clinical Cancer Research 27 (20), 5708-5717, 2021 | 9 | 2021 |
